Markets
Nia Warfield, Luke Kawa

Everything goes wrong for US stocks, with the S&P 500 posting its biggest loss in months

A trio of troubles sank US stocks on Friday: Amazon’s lackluster guidance after the bell on Thursday, President Donald Trump’s plans for more tariff hikes starting August 7, and a string of poor economic data headlined by lower-than-expected job growth in July.

The S&P 500 had its first daily move of at least 1% in 26 sessions, and it was to the downside: the benchmark index finished off 1.6%, while the Nasdaq 100 and Russell 2000 each slumped 2%.

Defensively oriented S&P sector ETFs — healthcare, consumer staples, and utilities — were the only ones to go positive on the session. Consumer discretionary and tech each slumped 2%, with seven sector ETFs falling at least 1%.

Gains were led by Monolithic Power, which rose 10%, and First Solar, which jumped 5.3% after the solar panel developer posted a surprise Q2 earnings beat and a sunnier full-year outlook. On the flip side: Coinbase helped lead declines with shares falling 16.9% after the largest US crypto exchange posted disappointing Q2 results on Thursday.

Sticking with earnings…

Amazon shares continued to stumble, falling 8% as investors focused on the tech giant’s weaker-than-expected operating income forecast for the current quarter and massive capex spend.

Moderna shares slipped 6.6% after the vaccine maker reported Q2 results that beat Wall Street estimates but lowered its full-year revenue guidance.

Exxon fell 1.8% after reporting better-than-expected Q2 earnings and sales early Friday, despite warning weeks ago that soft prices would crimp profits.

Riot Platforms fell 17% after the bitcoin mining company reported Q2 earnings after the bell Thursday that missed on revenue amid rising mining costs. 

Outside of earnings…

Joby Aviation rose 3% after the air taxi maker announced a partnership with defense tech firm L3Harris Technologies to develop military aircraft. L3Harris shares closed flat.

Tesla shares ticked lower 1.8% lower after EV sales fell in Sweden, Denmark, the Netherlands, and France — marking the seventh straight monthly drop in those countries.

More Markets

See all Markets
markets
Luke Kawa

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Alphabet beat earnings and revenue expectations

Alphabet beat earnings and revenue expectations

Accordingly, shares of the custom chip specialist are soaring in after-hours trading.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Luke Kawa
12h
Qualcomm tumbles after releasing gloomy Q2 guidance thanks to memory chip supply crunch

Q1 results beat expectations, but the memory chip crunch looks to be weighing on the forward outlook.

A crowd of visitors at the Qualcomm ( Qualcomm is an...
Tasha Matsumoto
12h
Stocks continue to slide amid tech sell-off

Investors were once again in risk-off mode as tech and crypto continued to fall.

Chicago Bears fans react during the second half of a game against the Arizona Cardinals at State Farm Stadium on November 03, 2024 in Glendale, Arizona.
(J. Edward Moreno/Sherwood News)

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

J. Edward Moreno14h
markets
J. Edward Moreno

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly’s diabetes and weight-loss drugs have outsold Novo’s, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.
©2026 Sherwood Media, LLC